4-(3-fluoro-4-methoxyphenyl)but-3-en-2-one | 915287-54-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 4-(3-fluoro-4-methoxyphenyl)but-3-en-2-one
• 英文别名: (E)-4-(3-fluoro-4-methoxyphenyl)but-3-en-2-one
• CAS: 915287-54-6
• 化学式: C₁₁H₁₁FO₂
• 分子量: 194.206
• InChiKey: YHQFCAFNNHGABZ-ONEGZZNKSA-N

物化性质

• 熔点：
  96-97 °C(Solv: ethyl acetate (141-78-6))
• 沸点：
  323.7±27.0 °C(Predicted)
• 密度：
  1.127±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3-fluoro-4-methoxyphenyl)but-3-en-2-one 、 tert-butyl 1,2,3,4-tetrahydroisoquinoline-2-carboxylate 在 ammonium peroxydisulfate 、 tris(bipyridine)ruthenium(II) dichloride hexahydrate 作用下， 以 甲醇 为溶剂， 反应 12.0h， 以61%的产率得到tert-butyl (E)-1-(4-(3-fluoro-4-methoxyphenyl)-2-oxobut-3-en-1-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
  参考文献：
  名称：

  N-Boc-四氢异喹啉与 α,β-不饱和酮的光催化 Csp3–Csp3 交叉脱氢偶联

  摘要：

  开发了一种新型光催化N -Boc-四氢异喹啉与 α,β-不饱和酮的交叉脱氢偶联反应。这项研究提供了一种容易获得各种 C1 取代的四氢异喹啉的方法，这些四氢异喹啉可以进一步转化为具有广泛生物活性的天然产物骨架苯并[ a ]-quinolizine-2-ones。光催化剂的负载量低，氧化剂便宜且毒性较小。

  DOI：

  10.1039/d1ob00527h
• 作为产物：
  描述：

  3-氟-4-甲氧基苯甲醛 、 丙酮 在 sodium hydroxide 作用下， 以22%的产率得到4-(3-fluoro-4-methoxyphenyl)but-3-en-2-one
  参考文献：
  名称：

  Dehydrozingerone, Chalcone, and Isoeugenol Analogues as in Vitro Anticancer Agents

  摘要：

  Twenty-eight compounds related to dehydrozingerone ( 1), isoeugenol ( 3), and 2-hydroxychalcone ( 4) were synthesized and evaluated in vitro against human tumor cell replication. Except for isoeugenol analogues 27-35, most compounds exhibited moderate or strong cytotoxic activity against KB, KB-VCR ( a multidrug-resistant derivative), and A549 cell lines. In particular, chalcone 15 showed significant cytotoxic activity against the A549 cell line with an IC50 value of 0.6 mu g/mL. Furthermore, dehydrozingerone analogue 11 and chalcones 16 and 17 showed significant and similar cytotoxic activity against both KB (IC50 values of 2.0, 1.0, and 2.0 mu g/mL, respectively) and KB-VCR (IC50 values of 1.9, 1.0, and 2.0 mu g/mL, respectively) cells, suggesting that they are not substrates for the P-glycoprotein drug efflux pump.

  DOI：

  10.1021/np060252z

文献信息

• [EN] COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME<br/>[FR] MODES DE RÉALISATION DE COMPOSÉ POUR LE TRAITEMENT DE LA DÉGÉNÉRESCENCE RÉTINIENNE ET MODES DE RÉALISATION DE PROCÉDÉ DE PRÉPARATION ET DE MÉTHODES D'UTILISATION DE CELUI-CI
  申请人：US HEALTH

  公开号：WO2022006439A2

  公开（公告）日：2022-01-06

  Method embodiments are disclosed for treating retinal degeneration in a subject in need thereof. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of compound, and/or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, or tautomer thereof, selected from 3-(dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol hydrochloride or a compound having a structure according to a formula selected from Formula I, II, or III, as described herein. In some non-limiting examples, the subject has retinitis pigmentosa, LCA, Stargardt's macular dystrophy, cone-rod dystrophy, choroideremia or age-related macular degeneration.
• Photocatalyzed Csp³–Csp³ cross-dehydrogenative coupling of <i>N</i>-Boc-tetrahydroisoquinolines with α,β-unsaturated ketones
  作者：Na-Ri-Mei Ao、Xue-Qing Zhu、Chun-Xin Zhao、Ya-Ru Gao、Yong-Qiang Wang

  DOI：10.1039/d1ob00527h

  日期：——

  A novel photocatalyzed cross-dehydrogenative coupling reaction of N-Boc-tetrahydroisoquinolines with α,β-unsaturated ketones has been developed. This research provides an easy access to a variety of C1-substituted tetrahydroisoquinolines, which can be further transformed into benzo[a]-quinolizine-2-ones, the skeletons of natural products with a wide range of biological activities. The load of the photocatalyst

  开发了一种新型光催化N -Boc-四氢异喹啉与 α,β-不饱和酮的交叉脱氢偶联反应。这项研究提供了一种容易获得各种 C1 取代的四氢异喹啉的方法，这些四氢异喹啉可以进一步转化为具有广泛生物活性的天然产物骨架苯并[ a ]-quinolizine-2-ones。光催化剂的负载量低，氧化剂便宜且毒性较小。
• Dehydrozingerone, Chalcone, and Isoeugenol Analogues as in Vitro Anticancer Agents
  作者：Jin Tatsuzaki、Kenneth F. Bastow、Kyoko Nakagawa-Goto、Seiko Nakamura、Hideji Itokawa、Kuo-Hsiung Lee

  DOI：10.1021/np060252z

  日期：2006.10.1

  Twenty-eight compounds related to dehydrozingerone ( 1), isoeugenol ( 3), and 2-hydroxychalcone ( 4) were synthesized and evaluated in vitro against human tumor cell replication. Except for isoeugenol analogues 27-35, most compounds exhibited moderate or strong cytotoxic activity against KB, KB-VCR ( a multidrug-resistant derivative), and A549 cell lines. In particular, chalcone 15 showed significant cytotoxic activity against the A549 cell line with an IC50 value of 0.6 mu g/mL. Furthermore, dehydrozingerone analogue 11 and chalcones 16 and 17 showed significant and similar cytotoxic activity against both KB (IC50 values of 2.0, 1.0, and 2.0 mu g/mL, respectively) and KB-VCR (IC50 values of 1.9, 1.0, and 2.0 mu g/mL, respectively) cells, suggesting that they are not substrates for the P-glycoprotein drug efflux pump.